Cardiac symptoms and anxiety disorders: contributing factors and pharmacologic treatment.
Cardiac symptoms and anxiety disorders: contributing factors and pharmacologic treatment.
复制标题
心脏症状和焦虑症：影响因素和药物治疗。
DOI：
10.1016/0002-9149(87)90686-2
复制
发表时间：
1987
期刊：
影响因子：
--
通讯作者：
McLeod,DR
中科院分区：
文献类型：
--
作者：
Hoehn-Saric,R;McLeod,DR
焦虑可能对患有心血管疾病或易患心血管疾病的人的心血管系统产生有害影响。焦虑类型、体质特征和人格特征是影响焦虑的主要因素。因此，焦虑的治疗对心血管疾病患者有有益的影响。然而，通过药物减少焦虑，即使它包括躯体症状的主观改善，也不一定等同于对心血管系统的有益影响。三组药物在治疗焦虑症中的作用各不相同。抗抑郁药降低精神焦虑，但可能对心血管系统产生相反的作用，而β-肾上腺素能阻滞剂降低交感神经紧张度，但不影响精神焦虑。只有苯二氮卓类药物才具有这两种功能。由于躯体（包括心血管）变化的主观报告与生理变化的相关性很差，因此对新药的评估不应依赖于自我报告的心脏症状改善，而应包括客观指标。
Anxiety may have deleterious effects on the cardiovascular system in persons who have, or are predisposed to have, cardiovascular disease. Contributing factors consist of the type of anxiety, constitutional characteristics and personality traits. The treatment of anxiety thus has a beneficial effect on patients with cardiovascular disease. However, anxiety reduction through medication, even if it includes subjective improvement in somatic symptoms, should not necessarily be equated with beneficial effects on the cardiovascular system. Three groups of medication used in the treatment of anxiety have different effects. Antidepressants lower psychic anxiety but may have the opposite effect on the cardiovascular system, whereas β-adrenergic blockers lower sympathetic tone without affecting psychic anxiety. Only benzodiazepines fulfill both functions. Since subjective reports of somatic, including cardiovascular, changes correlate poorly with physiologic changes, assessment of new medications should not rely on self-reported improvement in cardiac symptoms but should include objective measures as well.